Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics chief "really pleased" with human trial data for new skin cream

“It is very difficult to change a healthy barrier and therefore the data showing improvement in some age groups gives us confidence in our partner discussions, and in seeking to develop future applications in disease conditions where the barrier is known to be poor such as eczema,” Dr Cath O’Neill said.
woman touching face
The company says there is further scope to optimise its cream

SkinBioTherapeutics PLC’s (LON:SBTX) chief executive Dr Cath O'Neill said she was “really pleased” with the results from the company’s first human study of its SkinBiotix cream.

The data revealed the product to be well tolerated and efficacious in certain age groups and at certain time points.

“It is very difficult to change a healthy barrier and therefore the data showing improvement in some age groups gives us confidence in our partner discussions, and in seeking to develop future applications in disease conditions where the barrier is known to be poor such as eczema,” O’Neill said.

Hydration

The readout showed that the under 50s group saw a statistically significant increase in skin hydration at day 15, though at day 29 there was no difference in hydration across all the groups monitored.

There was also a small, but statistically significant decrease in transepidermal water loss at day 29 in the over 60s cohort.

“To show efficacy at this stage of development is very exciting since there is a lot of scope for us to further optimise the formulation, potentially altering the dose of the SkinBiotix to make it more suitable for different age groups,” said CEO O’Neill.

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use